EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
常見問題
EyeGene 今天的股價是多少?▼
185490.KQ 目前價格為 ₩1,744 KRW,過去 24 小時上漲了 +2.29%。在圖表上更密切關注 EyeGene 股價表現。
EyeGene 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 KOSDAQ 交易所,EyeGene 的股票以代號 185490.KQ 進行交易。
EyeGene 的股價在上漲嗎?▼
185490.KQ 股票較上週上漲 +3.81%,本月下跌 -9.07%,過去一年 EyeGene 下跌 -5.78%。
EyeGene 的市值是多少?▼
今天 EyeGene 的市值為 47.14B
EyeGene 上一季度的財報如何?▼
185490.KQ 上一季度的財報為每股 -49 KRW,預估為 不適用 KRW,帶來 不適用 的驚喜。下一季度的預估財報為每股 不適用 KRW。
EyeGene 去年的營收是多少?▼
EyeGene 去年的營收為 3.57BKRW。
EyeGene 去年的淨利是多少?▼
185490.KQ 去年的淨收益為 -15.71BKRW。
EyeGene 有多少名員工?▼
截至 2026年11月2日,公司共有 47 名員工。
EyeGene 位於哪個產業?▼
EyeGene從事於Energy產業。
EyeGene 何時完成拆股?▼
EyeGene 上次拆股發生於 2021年6月28日,比例為 1.2:1。
EyeGene 的總部在哪裡?▼
EyeGene 的總部位於 南韓 的 Seoul。